CN110461330A - 用于治疗亨廷顿氏病的PPARγ激动剂 - Google Patents

用于治疗亨廷顿氏病的PPARγ激动剂 Download PDF

Info

Publication number
CN110461330A
CN110461330A CN201880007571.4A CN201880007571A CN110461330A CN 110461330 A CN110461330 A CN 110461330A CN 201880007571 A CN201880007571 A CN 201880007571A CN 110461330 A CN110461330 A CN 110461330A
Authority
CN
China
Prior art keywords
subject
disease
huntington
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880007571.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·芬克
L·斯廷曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kohlros Biosciences Co Ltd
Original Assignee
Kohlros Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kohlros Biosciences Co Ltd filed Critical Kohlros Biosciences Co Ltd
Publication of CN110461330A publication Critical patent/CN110461330A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880007571.4A 2017-01-18 2018-01-18 用于治疗亨廷顿氏病的PPARγ激动剂 Pending CN110461330A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
CN110461330A true CN110461330A (zh) 2019-11-15

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880007571.4A Pending CN110461330A (zh) 2017-01-18 2018-01-18 用于治疗亨廷顿氏病的PPARγ激动剂

Country Status (13)

Country Link
US (1) US20190350918A1 (enExample)
EP (1) EP3570841A4 (enExample)
JP (1) JP2020505448A (enExample)
KR (1) KR20190122664A (enExample)
CN (1) CN110461330A (enExample)
AU (1) AU2018210165A1 (enExample)
BR (1) BR112019014529A2 (enExample)
CA (1) CA3050104A1 (enExample)
EA (1) EA201991716A1 (enExample)
IL (1) IL268008A (enExample)
MX (1) MX2019008535A (enExample)
SG (1) SG11201906644YA (enExample)
WO (1) WO2018136635A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US20050143416A1 (en) * 2003-10-03 2005-06-30 Kruk Henry T. Salts and polymorphs of a potent antidiabetic compound
CN1902185A (zh) * 2003-10-31 2007-01-24 舍林股份公司 噻唑烷酮类化合物、其制备方法以及作为药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
JP2008515978A (ja) * 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US20050143416A1 (en) * 2003-10-03 2005-06-30 Kruk Henry T. Salts and polymorphs of a potent antidiabetic compound
CN1902185A (zh) * 2003-10-31 2007-01-24 舍林股份公司 噻唑烷酮类化合物、其制备方法以及作为药物的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEX M DEPAOLI等: "Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?", 《DIABETES CARE》 *
JUAN CARLOS CORONA等: "PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease", 《FREE RADICAL BIOLOGY AND MEDICINE》 *
YANG YANG等: "The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *

Also Published As

Publication number Publication date
WO2018136635A1 (en) 2018-07-26
SG11201906644YA (en) 2019-08-27
AU2018210165A1 (en) 2019-08-01
KR20190122664A (ko) 2019-10-30
JP2020505448A (ja) 2020-02-20
EP3570841A1 (en) 2019-11-27
CA3050104A1 (en) 2018-07-26
IL268008A (en) 2019-09-26
US20190350918A1 (en) 2019-11-21
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04
MX2019008535A (es) 2019-12-02
EP3570841A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
JP6957602B2 (ja) 神経変性疾患のための治療薬
JP2014517050A5 (enExample)
JP2008519847A (ja) 運動障害の治療方法
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
CN1293573A (zh) 迟发性运动障碍和其它运动疾病的治疗方法
JP2024059863A (ja) リソソーム蓄積障害に関する医薬組成物及び使用
US20090149518A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
KR102549684B1 (ko) 신경퇴행성 질병에 대한 치료제
JP2002541198A (ja) 失禁の治療法
CN110461330A (zh) 用于治疗亨廷顿氏病的PPARγ激动剂
CN110996951A (zh) 治疗进行性核上性麻痹的PPARγ激动剂
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
TW202539621A (zh) 用於治療巴金森氏症的治療劑
JPH0143727B2 (enExample)
JP2021530567A (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ−メチル−ｄ−アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
WO2024211310A1 (en) Methods of dosing spinogenic compounds
Rizek et al. Management of Advanced Parkinson’s Disease
JPH07503972A (ja) 外傷後のストレスの治療用薬剤としてのブロファロミン
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
CN108025003A (zh) 前额叶皮质处理病症，步态和肢体障碍治疗
JP5080745B2 (ja) フマル酸ケトチフェンを含有する局所粘膜適用医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191115

WD01 Invention patent application deemed withdrawn after publication